Validity of an automated telephonic system to assess COPD exacerbation rates

European Respiratory Journal

Volumn 39, Issue 5, 2012, Pages 1090-1096

  Bischoff, Erik W M A ^a   Boer, Lonneke M ^a   Molema, Johan ^a   Akkermans, Reinier ^a   Van Weel, Chris ^a   Vercoulen, Jan H ^a   Schermer, Tjard R J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chronic obstructive pulmonary disease; Exacerbations; Sensitivity; Specificity

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; SALBUTAMOL;

AGED; ARTICLE; AUTOMATED TELEPHONIC EXACERBATION ASSESSMENT SYSTEM; AUTOMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DATA COLLECTION METHOD; DISEASE EXACERBATION; DRUG UTILIZATION; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE UTILIZATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PAPER DIARY CARD; PATIENT COMPLIANCE; PATIENT PREFERENCE; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY AND SPECIFICITY;

AGED; DISEASE PROGRESSION; FEMALE; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT PREFERENCE; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; TELEPHONE;

EID: 84860465538     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00057811     Document Type: Article

References (31)

1. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608-1613. (Pubitemid 30329036)
2. Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387-395. (Pubitemid 38624744)
3. Spencer S, Calverley PMA, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698-702. (Pubitemid 38618138)
4. Seemungal TA, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418-1422.
5. Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc Am Thorac Soc 2006; 3: 218-221. (Pubitemid 43670415)
6. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003; 97: Suppl. C, S3-S14. (Pubitemid 36266865)
7. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303. (Pubitemid 30245717)
8. Effing TW, Kerstjens HA, Monninkhof EM, et al. Definitions of exacerbations. Does it really matter in clinical trials on COPD? Chest 2009; 136: 918-923.
9. Trappenburg JCA, van Deventer AC, Troosters T, et al. The impact of using different symptom-based exacerbation algorithms in patients with COPD. Eur Respir J 2011; 37: 1260-1268.
10. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J 2003; 21: Suppl. 41, 46s-53s. (Pubitemid 36648154)
11. Hoogendoorn M, van Wetering CR, Schols AM, et al. Is INTERdisciplinary COMmunity-based COPD management (INTERCOM) cost-effective? Eur Respir J 2010; 35: 79-87.
12. Rutten FH, Zuithoff NP, Hak E, et al. b-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-887.
13. Pauwels R, Calverley P, Buist AS, et al. COPD exacerbations: the importance of a standard definition. Respir Med 2004; 98: 99-107. (Pubitemid 38181126)
14. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. www.goldcopd.org/ guidelines-global-strategy-for-diagnosis-management. html Date last accessed: January 2012. Date last updated: December 2011.
15. Wilkinson TM, Donaldson GC, Hurst JR, et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 1298-1303. (Pubitemid 39571857)
16. Boot CR, Vercoulen JH, van der Gulden JW, et al. Sick leave in patients with obstructive lung disease is related to psychosocial and work variables rather than to FEV1. Respir Med 2005; 99: 1022-1031. (Pubitemid 40796546)
17. Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204. (Pubitemid 17009877)
18. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852. (Pubitemid 35178607)
19. Sedeno MF, Nault D, Hamd DH, et al. A written action plan for early treatment of COPD exacerbations: an important component to the reduction of hospitalizations. COPD 2009; 6: 352-358.
20. Bischoff EW, Hamd DH, Sedeno M, et al. Effects of written action plan adherence on COPD exacerbation recovery. Thorax 2011; 66: 26-31.
21. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789. (Pubitemid 46294610)
22. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2007; 177: 19-26.
23. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
24. Knottnerus JA, van Weel C, Muris JW. Evidence base of clinical diagnosis: evaluation of diagnostic procedures. BMJ 2002; 324: 477-480. (Pubitemid 34169469)
25. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 842-846.
26. Aaron SD, Fergusson D, Marks GB, et al. Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Counting, analyzing and reporting exacerbations of COPD in randomized, controlled trials. Thorax 2008; 63: 122-128.
27. Grobbee DE, Hoes AW. Clinical Epidemiology. Principles, Methods, and Applications for Clinical Research. Massachusetts, Jones and Bartlett Publishers, 2009.
28. Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of COPD exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011; 183; 323-329.
29. Langsetmo L, Platt RW, Ernst P, et al. Under-reporting exacerbation of COPD in longitudinal cohort. Am J Respir Crit Care Med 2008; 177: 396-401.
30. Stone AA, Shiffman S, Schwartz JE, et al. Patient compliance with paper and electronic diaries. Control Clin Trials 2003; 24: 182-199. (Pubitemid 36412017)
31. McLean S, Nurmatov U, Liu JL, et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 7: CD007718.